Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | MLNR | O43193 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061553 | 0.82 | HRH3 (0.60) | HRH3PARP1PARP2 | |
| SCHEMBL3062510 | 0.81 | HRH3 (0.45) | HRH3PARP1PARP2HDAC1KCNH2 | |
| SCHEMBL3060977 | 0.80 | HRH3 (0.44) | HRH3PARP1PARP2ACVR1 | |
| SCHEMBL3059282 | 0.80 | KDM4E (0.51) | HRH3PARP1PARP2HDAC1ACVR1 | |
| SCHEMBL3066047 | 0.80 | CYP11B1 (0.50) | HRH3PARP1PARP2HDAC1ACVR1 | |
| SCHEMBL3056018 | 0.80 | HRH3 (0.56) | HRH3HDAC1KCNH2 | |
| SCHEMBL3051776 | 0.78 | HRH3 (0.48) | HRH3PARP1PARP2HDAC1ACVR1 | |
| Hydrochloric Acid SCHEMBL27786213 | 0.77 | HRH3 (0.47) | HRH3PARP1PARP2HDAC1ACVR1 | |
| SCHEMBL1743992 | 0.76 | HRH3 (0.53) | HRH3 | |
| SCHEMBL10332007 | 0.76 | SMN1; SMN2 (0.71) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | claimed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2166850-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | High Point Pharmaceuticals, LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2014656-A2 | New heteocyclic h3 antagonists | TRANSTECH PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885PARP1 1812/4885PARP2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.